← board
FTLF
distress 1/10 · well-funded / low risk$10.21-1%today-51% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
0%
Price & events
-38.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-8.5%
1W
-13.8%
1M
+6.4%
3M
-35.2%
6M
-24.6%
1Y
-38.5%
2Y
+94.5%
5Y
+278.1%
All
Overview
- Market Cap
- $95.88M
- Enterprise Value
- $128.25M
- Volume
- 174
- 52 Week Range
- $8.88 – $20.76
- Total Shares
- 9.39M
- Float Shares
- 2.90M
- Short %
- 1.79%
- % Held by Insiders
- 15.19%
- % Held by Institutions
- 58.50%
- RVOL
- 0.00x
- Beta
- 0.01
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-13earningsEarningsEarnings releaseyahoo
- 2025-07-31partnershipBankruptcy Court approved FitLife's purchase of Irwin Naturals assets for $42.5M.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-04-02Lake StreetBuy
- 2025-08-15Roth CapitalBuy
- 2025-03-17Lake StreetBuy
Competitors
- none identified
Recent news
- 2026-07-20Price to book forward of FitLife Brands, Inc. – FWB:QO80 - TradingView
- 2026-07-11FitLife Brands (FTLF) Proxy filing Summary - Quartr
- 2026-06-28FTLF | FitLife Brands, Inc. Common Executive Compensation - Quiver Quantitative
- 2026-06-28FitLife Brands, Inc.(NasdaqCM:FTLF) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
- 2026-06-28FitLife Brands, Inc.(NasdaqCM: FTLF) dropped from Russell 2500 Growth Benchmark - marketscreener.com
- 2026-06-27FitLife Brands (FTLF) Stock Fair Value Moves Lower After Analysts Cut Growth Views - Yahoo Finance
- 2026-06-25FitLife Brands: The Acquisition Of Irwin Naturals Is Already Paying Off (NASDAQ:FTLF) - Seeking Alpha
- 2026-06-20FitLife Brands (FTLF) Proxy Filing Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.